Acer Therapeutics Probability of Future Stock Price Finishing Over 2.62
ACERDelisted Stock | USD 0.84 0.02 2.33% |
Acer |
Acer Therapeutics Target Price Odds to finish over 2.62
The tendency of Acer Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to move over $ 2.62 or more in 90 days |
0.84 | 90 days | 2.62 | close to zero percent |
Based on a normal probability distribution, the odds of Acer Therapeutics to move over $ 2.62 or more in 90 days from now is close to zero percent (This Acer Therapeutics probability density function shows the probability of Acer Stock to fall within a particular range of prices over 90 days) . Probability of Acer Therapeutics price to stay between its current price of $ 0.84 and $ 2.62 at the end of the 90-day period is about 66.66 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.03 . This suggests Acer Therapeutics market returns are sensible to returns on the market. As the market goes up or down, Acer Therapeutics is expected to follow. Additionally Acer Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Acer Therapeutics Price Density |
Price |
Predictive Modules for Acer Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Acer Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acer Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Acer Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Acer Therapeutics is not an exception. The market had few large corrections towards the Acer Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Acer Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Acer Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.25 | |
β | Beta against Dow Jones | 1.03 | |
σ | Overall volatility | 0.07 | |
Ir | Information ratio | -0.06 |
Acer Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Acer Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Acer Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.Acer Therapeutics is not yet fully synchronised with the market data | |
Acer Therapeutics has some characteristics of a very speculative penny stock | |
Acer Therapeutics has a very high chance of going through financial distress in the upcoming years | |
Acer Therapeutics currently holds 11.86 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Acer Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Acer Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
Net Loss for the year was (26.24 M) with profit before overhead, payroll, taxes, and interest of 1.26 M. | |
Acer Therapeutics currently holds about 14.47 M in cash with (30.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Roughly 14.0% of Acer Therapeutics shares are held by company insiders |
Acer Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Acer Stock often depends not only on the future outlook of the current and potential Acer Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acer Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 15.8 M | |
Cash And Short Term Investments | 2.3 M |
Acer Therapeutics Technical Analysis
Acer Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Acer Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Acer Therapeutics. In general, you should focus on analyzing Acer Stock price patterns and their correlations with different microeconomic environments and drivers.
Acer Therapeutics Predictive Forecast Models
Acer Therapeutics' time-series forecasting models is one of many Acer Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Acer Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Acer Therapeutics
Checking the ongoing alerts about Acer Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Acer Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Acer Therapeutics is not yet fully synchronised with the market data | |
Acer Therapeutics has some characteristics of a very speculative penny stock | |
Acer Therapeutics has a very high chance of going through financial distress in the upcoming years | |
Acer Therapeutics currently holds 11.86 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Acer Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Acer Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
Net Loss for the year was (26.24 M) with profit before overhead, payroll, taxes, and interest of 1.26 M. | |
Acer Therapeutics currently holds about 14.47 M in cash with (30.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Roughly 14.0% of Acer Therapeutics shares are held by company insiders |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |